









Markets
/
Stocks
/
nasdaq-wve
/

WAVE Life Sciences Ltd

WVE

13.450USD

+0.700+5.49%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.16BMarket Cap

LossP/E TTM



WAVE Life Sciences Ltd

13.450

+0.700+5.49%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of WAVE Life Sciences Ltd

Currency: USD Updated: 2026-02-06

Key Insights

WAVE Life Sciences Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 110 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.81.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

WAVE Life Sciences Ltd's Score

Industry at a Glance

Industry Ranking

110 / 392

Overall Ranking

240 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

WAVE Life Sciences Ltd Highlights

StrengthsRisks

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2867.99% year-on-year.

Undervalued

The company’s latest PE is -20.65, at a low 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 87.80K shares of this stock.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

33.813

Target Price

+153.66%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of WAVE Life Sciences Ltd is 6.17, ranking 285 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 7.61M, representing a year-over-year increase of 199.11%, while its net profit experienced a year-over-year increase of 12.83%.

Score

Industry at a Glance

Previous score

6.17

Change



Financials

8.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.38

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

WAVE Life Sciences Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of WAVE Life Sciences Ltd is 6.44, ranking 280 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -20.65, which is -91.55% below the recent high of -1.74 and -58.44% above the recent low of -32.71.

Score

Industry at a Glance

Previous score

6.44

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of WAVE Life Sciences Ltd is 8.63, ranking 90 out of 392 in the Biotechnology & Medical Research industry. The average price target is 23.00, with a high of 36.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.63

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

33.813

Target Price

+153.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

WAVE Life Sciences Ltd

WVE

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of WAVE Life Sciences Ltd is 7.10, ranking 102 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.43 and the support level at 12.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.72

Change

0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.120

Sell

RSI(14)

47.627

Neutral

STOCH(KDJ)(9,3,3)

37.326

Neutral

ATR(14)

0.806

High Vlolatility

CCI(14)

-22.602

Neutral

Williams %R

55.224

Sell

TRIX(12,20)

-0.599

Sell

StochRSI(14)

88.149

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

13.332

Buy

MA10

13.195

Buy

MA20

13.560

Sell

MA50

14.086

Sell

MA100

10.737

Buy

MA200

9.159

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of WAVE Life Sciences Ltd is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 77.83%, representing a quarter-over-quarter decrease of 2.94%. The largest institutional shareholder is Lee Ainslie, holding a total of 8.39M shares, representing 4.59% of shares outstanding, with 14.33% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

GSK plc

18.25M

+8.76%

RA Capital Management, LP

18.22M

Adage Capital Management, L.P.

14.57M

-2.99%

BlackRock Institutional Trust Company, N.A.

8.73M

-0.27%

Maverick Capital, Ltd.

Star Investors

8.39M

+1.58%

Driehaus Capital Management, LLC

6.30M

-3.57%

Shin Nippon Biomedical Laboratories Ltd

5.71M

M28 Capital Management LP

5.66M

Emerald Advisers LLC

4.76M

-8.31%

Kynam Capital Management LP

4.56M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of WAVE Life Sciences Ltd is 1.66, ranking 295 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -1.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. WAVE Life Sciences Ltd’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.